Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received simultaneous approval for both Part 1 (clinical design) and Part 2 (trial sites and execution) of its Phase 3 Clinical Trial Application (CTA) for CT-P55, a Cosentyx biosimilar candidate, from the European Medicines Agency (EMA).
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Approval of Part 1 & Part 2 Review for Phase 3 Clinical Trial Application of CT-P55 (Cosentyx Biosimilar) in Europe
- Reviewing Authority: European Medicines Agency (EMA)
- Application & Approval Dates (Local Time): Application Date 2024-10-11 / Clearance Date 2025-02-17
- Confirmation Date: 2025-02-18 (Date confirmed via CTIS)
- Clinical Trial Details
- Study Title: A Randomized, Active-Controlled, Double-Blind Phase 3 Trial to Compare the Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate-to-Severe Plaque Psoriasis
- Phase: Global Phase 3
- Target Indication: Plaque psoriasis
- Registration Number: EU CT number 2024-513348-27-00
- Patient Count: 375 subjects
- Duration: 56 weeks
- Purpose: To demonstrate biosimilarity between CT-P55 and the reference drug Cosentyx in terms of efficacy and safety
- Regulatory Process & Investment Risks
- Under EU clinical trial regulations, both Part 1 (assessment of clinical design) and Part 2 (assessment of trial sites and execution) have received simultaneous final clearance, enabling immediate initiation of the trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Patient Recruitment and Clinical Trial Progress in Europe
This disclosure serves as official notification that both Part 1 and Part 2 of the European Phase 3 CTA have been cleared, fulfilling all regulatory requirements to initiate actual clinical testing. Tracking whether patient enrollment and clinical trial milestones proceed according to schedule is important for assessing the actual implementation of the approved trial plan. Relevant updates can be confirmed through subsequent periodic reports or official IR announcements.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
